Targeting α-Synuclein as a therapy for Parkinson's disease: The battle begins

Movement Disorders

Volumn 32, Issue 2, 2017, Pages 203-207

  Olanow, C Warren ^a,b   Kordower, Jeffrey H ^c,d  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Clintrex LLC   (United States)

^c RUSH MEDICAL COLLEGE   (United States)

^d VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO N2 [1 (5 FLUORO 2 PYRIMIDINYL)ETHYL] N4 (5 METHYL 1H PYRAZOL 3 YL) 2,4 PYRIMIDINEDIAMINE; ALPHA SYNUCLEIN; ANTIPARKINSON AGENT; BELNACASAN; PRX 002; UNCLASSIFIED DRUG;

ARTICLE; DRUG TARGETING; HUMAN; PARKINSON DISEASE; PRION DISEASE; PRIORITY JOURNAL; NERVE CELL; SUBSTANTIA NIGRA;

ALPHA-SYNUCLEIN; HUMANS; NEURONS; PARKINSON DISEASE; SUBSTANTIA NIGRA;

EID: 85013040818     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26935     Document Type: Article

References (47)

1. Schenk D, Koller M, Ness D, et al. First-in-human assessment of PRX002, an anti–α-synuclein monoclonal antibody, in healthy volunteers. Mov Disord 2016 [Epub ahead of print].
2. Olanow CW, Prusiner SB. Is Parkinson's disease a prion disorder? Proc Natl Acad Sci U S A 2009;106:12571-12572.
3. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-2047.
4. Singleton AB, Farrer M, Johnson J, et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003;302:841.
5. Kirik D, Rosenblad C, Burger C, et al. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J Neurosci 2002;22:2780-2791.
6. Spillantini MG, Schmidt ML, Lee VM, et al. Alpha-synuclein in Lewy bodies. Nature 1997;388:839-840.
7. Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211.
8. Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 2008;14:504-506.
9. Li JY, Englund E, Holton JL, et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med 2008;14:501-503
10. Olanow CW, Brundin P. Alpha synuclein, prions, and Parkinson's disease. Mov Disord 2013;28:31-40.
11. Desplats P, Lee HJ, Bae EJ, et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A 2009;106:13010-13015.
12. Luk KC, Kehm VM, Zhang B, et al. Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice. J Exp Med 2012;209:975-986.
13. Volpicelli-Daley LA, Luk KC, Patel TP, et al. Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 2011;72:57-71.13.
14. Luk KC, Kehm V, Carroll J, et al. Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 2012;338:949-953.
15. Holmqvist S, Chutna O, Bousset L, et al. Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats. Acta Neuropathol 2014:128:805-820.
16. Rey NL, Steiner JA, Maroof N, et al. Widespread transneuronal propagation of α-synucleinopathy triggered in olfactory bulb mimics prodromal Parkinson's disease. J Exp Med 2016;213:1759-1778.
17. Ulusoy A, Phillips RJ, Helwig M, et al. Brain-to-stomach transfer of α-synuclein via vagal preganglionic projections. Acta Neuropathol 2016 [Epub ahead of print].
18. Mougenot AL, Nicot S, Benscik A, et al. Prion-like acceleration of a synucleinopathy. Neurobiol Aging 2012;33:2225-2228.
19. Watts JC, Giles K, Oehler A, et al. Transmission of multiple system atrophy prions to transgenic mice. Proc. Natl. Acad. Sci. U S A 2013;110:19555-19560.
20. Recassens A, Dehay B, Bove J, et al. Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys. Ann. Neurol 2014;75:351-362.
21. Valera E, Masliah E. Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies. Pharmacol Ther 2013;138:311-322.
22. Masliah E, Rockenstein E, Adame A, et al. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron 2005;46:857-868.
23. Masliah E, Rockenstein E, Mante M, et al. Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One 2011;6:e19338.
24. Mandler M, Valera E, Rockenstein E, et al. Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials. Acta Neuropathol 2014;127:861-879.
25. Lindstrom V, Fagerqvist T, Nordstrom E, et al. Immunotherapy targeting alpha-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] alpha-synuclein mice. Neurobiol Dis 2014;69:134-143.
26. Bae EJ, Lee HJ, Rockenstein E, et al. Antibody-aided clearance of extracellular alpha- synuclein prevents cell-to-cell aggregate transmission. J Neurosci 2012;32:13454-13469.
27. Tran HT, Chung CH, Iba M, et al. Alpha-synuclein immunotherapy blocks uptake and templated propagation of misfolded alpha-synuclein and neurodegeneration. Cell Rep 2014;7:2054-2065.
28. Mao X, Ou MT, Karuppagounder SS, Kam TI, et al. Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science 2016;353:
29. Games D, Valera E, Spencer B, et al. Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models. J Neurosci 2014;34:9441-9454.
30. Schneeberger A, Mandler M, Mattner F, Schmidt W. Vaccination for Parkinson's disease. Parkinsonism Relat Disord 2012;18 (Suppl 1):S11-S13.
31. Price DL, Wrasidlo W, Tsigelny I, et al. Novel structure based designed compound reduces accumulation of toxic alpha-synuclein and improves deficits in a transgenic murine model of PD/DLB. Society for Neuroscience, 2011; Abstract 357.25.
32. Spencer B, Emadi S, Desplats P, et al. ESCRT-mediated uptake and degradation of brain-targeted alpha-synuclein single chain antibody attenuates neuronal degeneration in vivo. Mol Ther 2014;22:1753-1767.
33. Spencer B, Williams S, Rockenstein E, et al. α-synuclein conformational antibodies fused to penetratin are effective in models of Lewy body disease. Ann Clin Transl Neurol 2016 16;3:588-606.
34. Cremades N, Cohen SI, Deas E, et al. Direct observation of the interconversion of normal and toxic forms of α-synuclein. Cell 2012;149:1048-1059
35. McNaught KS, Olanow CW, Halliwell B, et al. Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat Rev Neurosci 2001;2:589-594.
36. Dehay B, Martinez-Vicente M, Caldwell GA, et al. Lysosomal impairment in Parkinson's disease. Mov Disord 2013;28:725-732.
37. Chu Y, Dodiya H, Aebischer P, Olanow, CW, Kordower, JH. Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions. Neurobiol Dis 2009;35:385-98.
38. Schapira AH. Glucocerebrosidase and Parkinson disease: recent advances. Mol Cell Neurosci 2015;66:37-42.
39. Migdalska-Richards A, Daly L, Bezard E, Schapira AH. Ambroxol effects in glucocerebrosidase and α-synuclein transgenic mice. Ann Neurol 2016;80:766-775.
40. Collier TJ, Redmond DE Jr, Steece-Collier K, et al. Is alpha-synuclein loss-of-function a contributor to Parkinsonian pathology. Evidence from non-human primates. Front Neurosci 2016;10:12.
41. McGeer PL, McGeer EG. Glial reactions in Parkinson's disease. Mov Disord 2008;23:474-483
42. Olanow CW. Goetz CG, Kordower JH, et al. A double blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 2003;54:403-414.
43. Thome AD, Harms AS, Volpicelli-Daley LA, Standaert DG. MicroRNA-155 Regulates alpha-synuclein-induced inflammatory responses in models of Parkinson disease. J Neurosci 2016;36:2383-90.
44. Qin H, Buckley J, Li X, et al. Inhibition of the JAK/STAT Pathway protects against α-synuclein-induced neuroinflammation and dopaminergic neurodegeneration. J Neurosci 2016;36:5144-59.
45. Sampson TR, Debelius JW, Thron T, et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease. Cell 2016;167:1469-1480.
46. Wang W, Nguyen LT, Burlak C, et al. Caspase-1 causes truncation and aggregation of the Parkinson's disease-associated protein α-synuclein. Proc Natl Acad Sci U S A 2016;113:9587-9592.
47. Bassil F, Fernagut PO, Bezard E, et al. Reducing C-terminal truncation mitigates synucleinopathy and neurodegeneration in a transgenic model of multiple system atrophy. Proc Natl Acad Sci U S A 2016;113:9593-9598.